Skip to content

Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up

Implementing a Multilevel Intervention to Accelerate Colorectal Cancer Screening and Follow-up in Federally Qualified Health Centers Using a Stepped Wedge Design

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04514341
Enrollment
4
Registered
2020-08-14
Start date
2020-09-01
Completion date
2023-12-31
Last updated
2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Keywords

Multilevel intervention, Stepped wedge design, Implementation strategy, Federally qualified health center

Brief summary

Screening for colorectal cancer (CRC) not only detects disease early when treatment is more effective but also prevents cancer by finding and removing precancerous polyps. Because many of our nation's most disadvantaged and vulnerable individuals obtain health care at federally qualified health centers, these centers play a significant role in increasing CRC screenings among the most vulnerable populations. Furthermore, the full benefits of cancer screenings must include timely and appropriate follow-up of abnormal results. Thus, the purpose of this study is to implement a multilevel intervention to increase rates of CRC screenings, follow-ups, and referrals-to-care in federally qualified health centers (FQHCs). Also, we will examine the implementation strategies used to support the implementation process and their contribution to the adoption, implementation, and sustainment of the multilevel intervention. The multilevel intervention will target three different levels of influences: organization, provider, and individual. It will have multiple components, including provider and staff education, provider reminder, provider assessment and feedback, patient reminder, and patient navigation. This study is a multilevel, three-phase, stepped wedge cluster randomized trial with four clusters of clinics from four different FQHCs. Our FQHC partners together have 40 primary care clinics and 130 primary care providers. During Phase 1, there will be a 3-month waiting period during which no intervention components will be implemented. After the 3-month waiting period, we will randomize two clusters of clinics to cross from the control to the intervention and the remaining two clusters to follow three months later. All clusters of clinics will stay at the same phase for nine months, followed by a 3-month transition period, and then cross over to the next phase. In Phase 1, we will implement provider and staff education sessions. In Phase 2, we will add provider reminders, patient reminders, and provider assessment and feedback. We will add patient navigation during the last phase. Single level interventions are often insufficient at leading to sustainable changes. Multilevel interventions are needed to address multilevel contextual influences simultaneously. How to take advantage of multilevel interventions and how to implement such interventions and evaluate their effectiveness are the ultimate goals of this study.

Detailed description

A. BACKGROUND A1. Colorectal cancer control and FQHCs Screening for CRC not only detects disease early when treatment is more effective but also prevents cancer by finding and removing precancerous polyps. Despite strong evidence to support CRC screening, nationally, only 68.8% of adults had up to date screening in 2018 \[1\]. This figure is even lower among racial/ethnic minorities and people who live in poverty \[2-5\]. Racial/ethnic minorities and people with low social-economic status often lack health insurance and a regular source of care. These populations also disproportionately receive health care in safety-net settings, such as federally qualified health centers (FQHCs) \[6-7\]. In 2018, FQHCs served 28 million patients, of whom 23% were uninsured, 63% were racial/ethnic minorities, and 91% were living below 200% poverty level \[8\]. Thus, FQHCs play a significant role in increasing CRC screening among the most vulnerable populations. A2. Challenges of colorectal cancer control in FQHCs Due to the cost and limited availability of specialty services combined with patient preferences, FQHCs often promote non-invasive screening methods, such as fecal occult blood test (FOBT) or fecal immunochemical tests (FIT), as the modality for screening \[9-12\]. To achieve the benefits of CRC screening using FOBT/FIT, timely follow-up of positive results must occur. While no national estimates of the proportion of individuals without follow-up diagnostic evaluation after receiving a positive FOBT/FIT exist, several studies report follow-up rates ranging from less than 50% to 90% within one year of a positive test \[13-22\], with integrated health care systems exhibiting higher follow-up rates by 12 months (82%-86%) compared to FQHCs (56%-58%) \[23-24\]. A3. Multilevel influences on cancer screening behavior Individuals live and seek care in a complex environment, and multiple levels of contextual influences may affect individual decisions and actions \[25-26\]. Multilevel interventions target changes in more than one contextual level (e.g., organization, provider, and patient levels) to influence health behavior, health care practice, and health outcomes \[27-28\]. Although the call for multilevel interventions has increased \[29-31\], there is still a lack of evidence addressing how to implement multilevel interventions or how interventions at multiple levels interact and affect health outcomes. B. STUDY OBJECTIVES The overall objective of this study is to provide the evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care at federally qualified health centers, and to understand how to improve the adoption, implementation, and sustainment of these interventions. In this study, we will test the effectiveness of our multilevel intervention while simultaneously observing and gathering information on the implementation process. The selection of our multilevel intervention components is based on extensive literature review, the strength of evidence, and findings from our previous studies and projects. The multilevel intervention will target three different levels of influence (organization, provider, and individual) to improve rates of CRC screening, follow-up, and referral-to-care at our partner FQHCs. Our multilevel intervention will have multiple components, including provider and staff education, provider reminder, provider assessment and feedback, patient reminder, and patient navigation. The aims this study are fourfold: (1) use a stepped wedge design to implement a multilevel intervention in three phases, (2) collect quarterly data to track changes over time, (3) evaluate the implementation process and the effectiveness of implementation strategies through observations, interviews, and annual survey, and (4) evaluate the effectiveness of the multilevel intervention using multilevel and longitudinal modeling. C. METHODS CRC screening and follow-up processes are complex and include several steps and interfaces. However, very few interventional studies have simultaneously targeted patient-, provider-, and organization-level factors. Interventions that focus on reducing barriers across several levels will likely be more effective for increasing rates of CRC screening, follow-up, and referral-to-care. C1. Multilevel Intervention and Implementation Strategy Provider Level Component Provider education Numerous studies indicate the importance of physician recommendation in influencing a patient's CRC screening decision \[31-44\], and this factor is a primary predictor for patient adherence with screening guidelines \[45-47\]. The research team will provide tailored education and guidance on best practices for participating health professionals. The educational sessions will focus on CRC risk assessment, screening guidelines, cultural competency, shared decision making, and communication skills using an academic detailing approach. The academic detailing approach involves trained experts visiting health care professionals in their settings to provide tailored education and guidance on best practices, which have shown to have a significant effect on increasing rates of CRC screening \[48-53\]. Each session will last about 15 to 20 minutes and will take place during routine staff and provider meetings. These academic detailing sessions will be ongoing throughout the study period. Provider assessment and feedback We will combine academic detailing with practice facilitation, which includes assessment and feedback on aggregate and individual provider screening behavior and practice performance \[54\]. The reports will include CRC screening order rates, screening completion rates, follow-up rates for abnormal results, and referral to oncology care. Providers will be able to see each other's performances, which allows providers to compare and learn from each other's successes. Provider reminder Given the multitude of competing priorities during a patient encounter, CRC screening recommendations can be overlooked. A provider prompt generated electronically or manually by staff members will be implemented to remind providers to screen their eligible patients. Provider prompts have been shown to increase CRC screening rates \[55\]. C2. Organization and Individual Level Component Patient reminder Provider recommendation alone does not guarantee the completion of CRC screening, which involves patient compliance. We will implement a patient reminder component using a text-based platform, also known as short message service (SMS), to engage and remind patients to complete the screening. For patients who use colonoscopy as a screening method, the SMS will also include instruction on bowel preparation and dietary restrictions five days before the procedure. Studies have demonstrated that SMS patient reminders not only had a positive impact on screening rates but also improved the quality of bowel preparation \[56-61\]. Patient navigation Patient navigation services will address both organization and individual influences. Patient navigation focuses on eliminating barriers by guiding a patient through a complex healthcare system, addressing education, sociocultural, and logistical needs using trained staff. We will hire and train two full-time CRC navigators and adapt and modify the well-studied New Hampshire Colorectal Cancer Screening Program (NHCRCSP) Patient Navigator Model \[62-64\]. C3. Implementation Strategy The effectiveness of an intervention, in part, depends on the strength of the implementation process. We will conduct a pre-implementation organizational readiness assessment (ORA). We will use the Consolidated Framework for Implementation Research (CFIR) to guide our ORA. We will conduct key informant interviews with health system leadership and clinic leaders to evaluate: 1) current CRC screening workflow, 2) CRC data capturing and validation process, and 3) capacity and resources available to support the implementation. Also, we will conduct a readiness survey with clinical providers and support staff to assess organizational climate and culture. Our 29 survey items were adapted and modified from validated instruments65-68 that measured CFIR constructs using a Delphi method. Effective strategies to support the implementation process is critical. Implementation strategies are actions taken to enhance the adoption, implementation, and sustainability of evidence-based interventions. We will use different implementation strategies to implement our multilevel intervention. Finally, we will implement our multilevel, multicomponent intervention in three phases along the CRC screening continuum. In Phase 1, we will collect baseline data and implement provider and staff education sessions. In Phase 2, we will add provider reminders, patient reminders, and provider assessment and feedback. We will add patient navigation during the last phase. C4. Study Design This study is a multilevel, three-phase, stepped wedge cluster randomized trial with four clusters of clinics from four different FQHCs. Our FQHC partners together have 40 primary care clinics and 130 primary care providers. During Phase 1, there will be a 3-month waiting period during which no intervention components will be implemented. After the 3-month waiting period, we will randomize two clusters of clinics to cross from the control to the intervention and the remaining two clusters to follow three months later. All clusters of clinics will stay at the same phase for nine months, followed by a 3-month transition period, and then cross over to the next phase. In Phase 1, we will implement provider and staff education sessions. In Phase 2, we will add provider reminders, patient reminders, and provider assessment and feedback. We will add patient navigation during the last phase. C5. Study Sites We will partner with four FQHCs, two in Illinois and two in Indiana. Together, our FQHC partners have 40 primary care clinics and 130 primary care providers and served 162,000 individual patients in 2018. Of the 162,000 patients, 78% were racial minorities, 93% live at or below 200% poverty, and 17% were uninsured. The CRC screening rates among our partners range from 25% to 43%. C6. Process Evaluation We will assess the potential causal and contextual factors that may be associated with observed outcomes at the provider and clinic levels. After completion of each phase, we will send all providers at our partner clinics a survey to assess their exposure to and experience with the intervention component. Furthermore, we will evaluate the changes in organizational culture and climate that may ascertain potential mechanisms of impact using the 29 survey items we developed based on the CFIR. C7. Data Analysis Plan We will conduct descriptive analyses, as well as within-group and between-group changes over time. Furthermore, to evaluate the four-component intervention effects, we will take a step-by-step approach. First, each intervention effect at each time phase will be estimated separately using linear-mixed effects models. The estimate of intervention effect in each model will be used to test if additional intervention component significantly affects outcome measures. Next, we will develop a grand model, including all intervention components simultaneously, in addition to the models described above.

Interventions

BEHAVIORALIntervention Phase 1: Provider and Staff education

In Phase 1, CRC control experts will identify critical messages on CRC, screening guidelines, and methods, and provide educational training to providers and staff in our partner FQHCs before implementing any intervention components. Additionally, the research team will provide refresher sessions and offer yearly training in CRC-relevant topics, including CRC and genetics.

BEHAVIORALIntervention Phase 2: Provider and staff education + Patient reminder

In Phase 2, we will add a patient reminder component using short message services (SMS) to engage and remind patients to complete the screening. For patients who use colonoscopy as a screening method, the SMS will also include instructions on bowel preparation and dietary restrictions for five days prior to the procedure.

BEHAVIORALIntervention Phase 3: Provider and Staff education + Patient reminder + Patient navigation

In Phase 3, we will add patient navigation services, which will address both organizational and individual barriers to obtaining screening.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Milton S. Hershey Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Eligibility for Federally Qualified Health Centers (FQHCs) Inclusion criteria: * Located in Illinois or Indiana * Provide adult primary care * Serve patients between the ages of 50 and 75 years * Able to provide patient-level data

Exclusion criteria

* Located outside Illinois or Indiana * Do not provide adult primary care * Unable to provide patient-level data Eligibility for patients whom our FQHC partners serve: Inclusion criteria: * Between the ages of 50 and 75 * At general risk for colorectal cancer

Design outcomes

Primary

MeasureTime frameDescription
CRC Screening RateFrom date of randomization until the last subject completed the study. This could have been up to 36 months.The number of patients aged 50-75 years who were up-to-date with colorectal cancer screening during each implementation phase.
CRC Screening Ordering RateFrom date of randomization until the date subject completed the study. This could have been up to 36 months.The number of patients between the ages of 50 and 75 who needed CRC screening and received a screening order (excluding participants who received an order but have already been up to date with screening ) during each implementation phase.
CRC Screening Completion RateFrom date of randomization until the date subject completed the study. This could have been up to 36 months.The number of patients between the ages of 50 and 75 who needed CRC screening, received an order for screening, and completed the screening during each implementation phase.

Secondary

MeasureTime frameDescription
Provider Education ParticipationFrom the date of the first education session until the completion of the last education sessions. This could have been up to 24 months.The number of providers who attended the annual education sessions during Phase 1 and Phase 2. To accommodate the COVID-19 restrictions, all sessions were delivered via Zoom, with multiple sessions scheduled within each FQHC based on clinic availability. Both groups received the education component simultaneously, with no delay in implementation.
Patient Reminder EnrollmentFrom the initiation of the SMS reminder system until the last participant enrolled. This could have been up to 30 months.The number of participants who received a FIT or colonoscopy order (excluding Cologuard, which provides its own reminder services) and subsequently enrolled in the short message service (SMS) reminder system during Phase 2 and Phase 3. The SMS platform was used to engage participants and remind them to complete their screenings; participants could opt out at any time by replying STOP.
Impact of Remote Patient Navigation ServicesFrom the navigation service initiated at the partner FQHC until the completion of the study, assessed up to 16 months.The number of participants who received remote navigation services (phone-based navigation) during Phase 3 and subsequently completed their screenings.

Countries

United States

Participant flow

Recruitment details

The study recruited four federally qualified health centers (FQHCs): two in Illinois and two in Indiana. Together, these four FQHCs operate 65 primary care clinics and served 131,233 individual patients in 2020. One FQHC from each state was randomly assigned to Group 1, while the remaining two were assigned to Group 2. Both groups received the intervention; the only distinction was that implementation in Group 2 was delayed by three months compared to Group 1.

Participants by arm

ArmCount
Group 1
The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3 Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol.
18,099
Group 1
The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3 Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol.
2
Group 2
The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3 Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol.
20,834
Group 2
The study was conducted at 4 federally qualified health centers (FQHCs): 2 in Illinois and 2 in Indiana. One FQHC from Illinois and one from Indiana were randomly assigned to Group 1, and the remaining two formed Group 2. Both groups received all intervention components, except that Group 2 began the intervention 3 months later than Group 1. The enrollment number reflects the total number of individual patients seen at each facility (FQHC) during each study phase. Because the study was conducted at the facility level, no individual consent or enrollment occurred. Additionally, the provider and staff education component was conducted at the facility (FQHC) level. Therefore, provider characteristics were not assessed at baseline and were not included in the Participant Flow or adverse event reporting. The intervention consists of three components: 1. Provider and staff education, 2. Patient reminders using short message services (SMS), and 3. Remote patient navigation (PN). Implementation was phased as follows: * Phase 0: No intervention components, baseline data collection only * Phase 1: Component 1 only * Phase 2: Components 1 + 2 * Phase 3: Components 1 + 2 +3 Baseline data collection was restricted to patients aged 50-75 years, the age group eligible for colorectal cancer screening in 2020. While provider and staff education sessions were part of the intervention components, no provider or staff characteristics were collected per protocol.
2
Total38,937

Withdrawals & dropouts

PeriodReasonFG000FG001
Step 2 (Months 19-21)In a 3-month delay period015,725
Step 4 (Months 31-33)In a 3-month delay period015,037

Baseline characteristics

CharacteristicGroup 2TotalGroup 1
Age, Continuous
FQHC 1
58.77 years
STANDARD_DEVIATION 6.138
58.96 years
STANDARD_DEVIATION 6.195
59.25 years
STANDARD_DEVIATION 6.272
Age, Continuous
FQHC 2
59.45 years
STANDARD_DEVIATION 6.126
59.79 years
STANDARD_DEVIATION 6.275
60.04 years
STANDARD_DEVIATION 6.374
Colorectal Cancer (CRC) Screening Up-to-date Rate
FQHC 1: CRC Screening Up to Date
2203 Participants5201 Participants2998 Participants
Colorectal Cancer (CRC) Screening Up-to-date Rate
FQHC 2: CRC Screening Up to Date
1817 Participants6456 Participants4639 Participants
CRC Order Rate
FQHC 1: CRC Screening Order Rate
3405 Participants5209 Participants1804 Participants
CRC Order Rate
FQHC 2: CRC Screening Order Rate
884 Participants4254 Participants3370 Participants
CRC Screening Completion Rate
FQHC 1: CRC Screening Completion Rate
1320 Participants2031 Participants711 Participants
CRC Screening Completion Rate
FQHC 2: CRC Screening Completion Rate
344 Participants2016 Participants1672 Participants
Ethnicity (NIH/OMB)
FQHC 1
Hispanic or Latino
3859 Participants6670 Participants2811 Participants
Ethnicity (NIH/OMB)
FQHC 1
Not Hispanic or Latino
8306 Participants13188 Participants4882 Participants
Ethnicity (NIH/OMB)
FQHC 1
Unknown or Not Reported
1741 Participants2991 Participants1250 Participants
Ethnicity (NIH/OMB)
FQHC 2
Hispanic or Latino
664 Participants1959 Participants1295 Participants
Ethnicity (NIH/OMB)
FQHC 2
Not Hispanic or Latino
3316 Participants7514 Participants4198 Participants
Ethnicity (NIH/OMB)
FQHC 2
Unknown or Not Reported
2948 Participants6611 Participants3663 Participants
Race (NIH/OMB)
FQHC 1
American Indian or Alaska Native
616 Participants684 Participants68 Participants
Race (NIH/OMB)
FQHC 1
Asian
177 Participants252 Participants75 Participants
Race (NIH/OMB)
FQHC 1
Black or African American
5111 Participants9551 Participants4440 Participants
Race (NIH/OMB)
FQHC 1
More than one race
1636 Participants2352 Participants716 Participants
Race (NIH/OMB)
FQHC 1
Native Hawaiian or Other Pacific Islander
75 Participants109 Participants34 Participants
Race (NIH/OMB)
FQHC 1
Unknown or Not Reported
1886 Participants3164 Participants1278 Participants
Race (NIH/OMB)
FQHC 1
White
4405 Participants6737 Participants2332 Participants
Race (NIH/OMB)
FQHC 2
American Indian or Alaska Native
77 Participants119 Participants42 Participants
Race (NIH/OMB)
FQHC 2
Asian
93 Participants159 Participants66 Participants
Race (NIH/OMB)
FQHC 2
Black or African American
1699 Participants3016 Participants1317 Participants
Race (NIH/OMB)
FQHC 2
More than one race
66 Participants259 Participants193 Participants
Race (NIH/OMB)
FQHC 2
Native Hawaiian or Other Pacific Islander
28 Participants39 Participants11 Participants
Race (NIH/OMB)
FQHC 2
Unknown or Not Reported
599 Participants909 Participants310 Participants
Race (NIH/OMB)
FQHC 2
White
4366 Participants11583 Participants7217 Participants
Region of Enrollment
United States
20834 participants38933 participants18099 participants
Sex/Gender, Customized
FQHC 1
Female
7478 Participants12497 Participants5019 Participants
Sex/Gender, Customized
FQHC 1
Male
5651 Participants8989 Participants3338 Participants
Sex/Gender, Customized
FQHC 1
Unknown
777 Participants1363 Participants586 Participants
Sex/Gender, Customized
FQHC 2
Female
4105 Participants9450 Participants5345 Participants
Sex/Gender, Customized
FQHC 2
Male
2823 Participants6629 Participants3806 Participants
Sex/Gender, Customized
FQHC 2
Unknown
0 Participants5 Participants5 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
deaths
Total, all-cause mortality
0 / 18,0990 / 20,8340 / 19,3180 / 18,8780 / 21,1020 / 15,7250 / 21,6020 / 15,037
other
Total, other adverse events
0 / 18,0990 / 20,8340 / 19,3180 / 18,8780 / 21,1020 / 15,7250 / 21,6020 / 15,037
serious
Total, serious adverse events
0 / 18,0990 / 20,8340 / 19,3180 / 18,8780 / 21,1020 / 15,7250 / 21,6020 / 15,037

Outcome results

Primary

CRC Screening Completion Rate

The number of patients between the ages of 50 and 75 who needed CRC screening, received an order for screening, and completed the screening during each implementation phase.

Time frame: From date of randomization until the date subject completed the study. This could have been up to 36 months.

Population: The overall number represents all participants who needed CRC screening and received an order across all study phases. The number analyzed reflects only participants contributing data at the reported milestone.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Group 1CRC Screening Completion RatePhase 1: Provider and Staff Educatioin3106 Participants
Group 1CRC Screening Completion RatePhase 2: Provider and Staff Education + Patient Reminders3031 Participants
Group 1CRC Screening Completion RatePhase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation3278 Participants
Group 2CRC Screening Completion RatePhase 1: Provider and Staff Educatioin1917 Participants
Group 2CRC Screening Completion RatePhase 2: Provider and Staff Education + Patient Reminders1749 Participants
Group 2CRC Screening Completion RatePhase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation1691 Participants
Primary

CRC Screening Ordering Rate

The number of patients between the ages of 50 and 75 who needed CRC screening and received a screening order (excluding participants who received an order but have already been up to date with screening ) during each implementation phase.

Time frame: From date of randomization until the date subject completed the study. This could have been up to 36 months.

Population: The overall number represents all participants who needed screening across all study Phases. The number analyzed reflects only participants contributing data at the reported phase.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Group 1CRC Screening Ordering RatePhase 1: Provide and Staff Education7012 Participants
Group 1CRC Screening Ordering RatePhase 2: Provider and Staff Education + Patient Reminders6458 Participants
Group 1CRC Screening Ordering RatePhase 3: Provide and Staff Education + Patient Reminders + Remote Patient Navigation6478 Participants
Group 2CRC Screening Ordering RatePhase 1: Provide and Staff Education5087 Participants
Group 2CRC Screening Ordering RatePhase 2: Provider and Staff Education + Patient Reminders4757 Participants
Group 2CRC Screening Ordering RatePhase 3: Provide and Staff Education + Patient Reminders + Remote Patient Navigation4611 Participants
Primary

CRC Screening Rate

The number of patients aged 50-75 years who were up-to-date with colorectal cancer screening during each implementation phase.

Time frame: From date of randomization until the last subject completed the study. This could have been up to 36 months.

Population: The overall number represents all participants across all study phases. The number analyzed reflects only participants contributing data at the reported phase.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Group 1CRC Screening RatePhase 1: Provider and Staff Education8611 Participants
Group 1CRC Screening RatePhase 2: Provider Education + Patient Reminder9438 Participants
Group 1CRC Screening RatePhase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation10720 Participants
Group 2CRC Screening RatePhase 1: Provider and Staff Education3989 Participants
Group 2CRC Screening RatePhase 2: Provider Education + Patient Reminder3186 Participants
Group 2CRC Screening RatePhase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation3303 Participants
Secondary

Impact of Remote Patient Navigation Services

The number of participants who received remote navigation services (phone-based navigation) during Phase 3 and subsequently completed their screenings.

Time frame: From the navigation service initiated at the partner FQHC until the completion of the study, assessed up to 16 months.

Population: The overall number represents the number of participants whom the navigators successfully contacted and spoke to during Phase 3.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Group 1Impact of Remote Patient Navigation Services529 Participants
Group 2Impact of Remote Patient Navigation Services284 Participants
Secondary

Patient Reminder Enrollment

The number of participants who received a FIT or colonoscopy order (excluding Cologuard, which provides its own reminder services) and subsequently enrolled in the short message service (SMS) reminder system during Phase 2 and Phase 3. The SMS platform was used to engage participants and remind them to complete their screenings; participants could opt out at any time by replying STOP.

Time frame: From the initiation of the SMS reminder system until the last participant enrolled. This could have been up to 30 months.

Population: The overall number represents the total number of participants who received a FIT or colonoscope order during the implementation of Phase 1 and Phase 2. The number analyzed reflects only the number of participants contributing data to the reported milestone.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Group 1Patient Reminder EnrollmentPhase 2: Provider and Staff Education + Patient Reminders4756 Participants
Group 1Patient Reminder EnrollmentPhase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation5198 Participants
Group 2Patient Reminder EnrollmentPhase 2: Provider and Staff Education + Patient Reminders4693 Participants
Group 2Patient Reminder EnrollmentPhase 3: Provider and Staff Education + Patient Reminders + Remote Patient Navigation3943 Participants
Secondary

Provider Education Participation

The number of providers who attended the annual education sessions during Phase 1 and Phase 2. To accommodate the COVID-19 restrictions, all sessions were delivered via Zoom, with multiple sessions scheduled within each FQHC based on clinic availability. Both groups received the education component simultaneously, with no delay in implementation.

Time frame: From the date of the first education session until the completion of the last education sessions. This could have been up to 24 months.

Population: The overall number represents the total number of providers invited to the education sessions during Phase 1 and Phase 2. The number analyzed reflects the number of providers invited to the education sessions during the reported phase.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Group 1Provider Education ParticipationPhase 1: Provider and Staff Education129 Participants
Group 1Provider Education ParticipationPhase 2: Provider and Staff Education + Patient Reminders126 Participants
Group 2Provider Education ParticipationPhase 1: Provider and Staff Education44 Participants
Group 2Provider Education ParticipationPhase 2: Provider and Staff Education + Patient Reminders89 Participants

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026